Gastroesophageal Junction Adenocarcinoma

CLINICAL_TRIALS trial_result · 2021-02-01

Clinical Trial Update: Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

Phase 2 trial evaluating raltitrexed with paclitaxel for gastric cancer and gastroesophageal junction adenocarcinoma has completed.

CLINICAL_TRIALS trial_result · 2020-12-24

Clinical Trial Update: Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 1]

Phase 1 trial evaluating andecaliximab as monotherapy and with anti-cancer agents in Japanese patients with gastric or gastroesophageal junc…

CLINICAL_TRIALS trial_result · 2020-12-19

Clinical Trial Update: A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer [Phase 1, Phase 2]

Phase 1/2 study evaluating emibetuzumab in combination with ramucirumab in various advanced cancers, with completed status and results poste…

CLINICAL_TRIALS trial_result · 2020-11-19

Clinical Trial Update: Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis [Phase 2]

Phase 2 trial evaluating ramucirumab plus paclitaxel as second-line therapy for metastatic gastric or gastroesophageal junction adenocarcino…

CLINICAL_TRIALS trial_result · 2020-06-22

Clinical Trial Update: Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer [Phase 2]

Phase 2 trial updating epacadostat plus pembrolizumab in metastatic or unresectable gastroesophageal junction or gastric cancer (completed; …

CLINICAL_TRIALS trial_result · 2020-06-17

Clinical Trial Update: A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer. [Phase 2, Phase 3]

A clinical trial comparing QL1604 plus nab-paclitaxel versus nab-paclitaxel alone in advanced gastric or gastroesophageal junction adenocarc…

CLINICAL_TRIALS trial_result · 2020-04-28

Clinical Trial Update: Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 3]

Phase 3 trial update evaluating andecaliximab with mFOLFOX6 as first-line therapy for advanced gastric or gastroesophageal junction adenocar…

CLINICAL_TRIALS trial_result · 2020-03-13

Clinical Trial Update: Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) [Phase 3]

Phase 3 trial evaluating pembrolizumab as first-line monotherapy and in combination for advanced gastric or gastroesophageal junction adenoc…

CLINICAL_TRIALS trial_result · 2020-02-19

Clinical Trial Update: Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction [Phase 3]

Phase 3 trial evaluating apatinib in combination with concurrent neoadjuvant chemoradiotherapy for gastroesophageal junction adenocarcinoma.

CLINICAL_TRIALS trial_result · 2020-02-19

Clinical Trial Update: A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction [Phase 2]

Phase 2 clinical trial evaluating apatinib plus concurrent neoadjuvant chemoradiotherapy for locally advanced HER-2 negative gastroesophagea…

CLINICAL_TRIALS research · 2020-02-19

Clinical Trial Update: Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study [Phase 2]

Phase 2 randomized study evaluating concurrent neoadjuvant chemoradiotherapy with trastuzumab for HER-2 positive gastroesophageal junction a…

CLINICAL_TRIALS trial_result · 2020-02-11

Clinical Trial Update: Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction [Phase 2]

Phase 2 trial evaluating conversion therapy with sintilimab plus CAPOX in unresectable locally advanced or limited metastatic stomach/EGJ ad…

CLINICAL_TRIALS trial_result · 2019-12-17

Clinical Trial Update: Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma [Phase 2]

Phase 2 trial evaluating tripletrumab plus SOX as first-line treatment for gastric cancer and gastroesophageal junction adenocarcinoma.

CLINICAL_TRIALS trial_result · 2019-12-10

Clinical Trial Update: Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma [Phase 2]

A Phase 2 trial evaluating a modified DCF regimen (docetaxel, cisplatin, and fluorouracil) in unresectable or metastatic gastric and gastroe…

FDA approval · 2019-06-28

FDA Approved: OGIVRI — Supplemental Application (Biocon Biologics Inc.)

FDA approved a supplemental Biologics License Application for OGIVRI (trastuzumab-dkst) from Biocon Biologics Inc., updating its labeling/pe…

CLINICAL_TRIALS trial_result · 2019-06-03

Clinical Trial Update: Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma [Phase 2]

Phase 2 trial evaluating avelumab plus paclitaxel or ramucirumab as second-line therapy for gastroesophageal junction adenocarcinoma and sto…

CLINICAL_TRIALS trial_result · 2019-02-27

Clinical Trial Update: MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer [Phase 2]

Phase 2 clinical trial evaluating metronomic capecitabine and docetaxel as second-line chemotherapy for advanced gastric/gastroesophageal ju…

CLINICAL_TRIALS trial_result · 2019-02-20

Clinical Trial Update: Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers [Phase 2]

Phase 2 trial assessing CRS-207 with pembrolizumab in gastric, gastroesophageal junction, and esophageal adenocarcinomas; study terminated w…

CLINICAL_TRIALS trial_result · 2019-02-15

Clinical Trial Update: A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

Phase 2 trial update for ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma has completed with results posted.

CLINICAL_TRIALS trial_result · 2018-12-19

Clinical Trial Update: A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer [Phase 2]

Phase 2 trial of ramucirumab with paclitaxel in gastric cancer completed; results posted in 2018.

CLINICAL_TRIALS trial_result · 2018-11-20

Clinical Trial Update: A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) [Phase 3]

Phase 3 trial comparing pembrolizumab to paclitaxel in advanced gastric/GEJ adenocarcinoma after platinum/fluoropyrimidine showed completed …

CLINICAL_TRIALS trial_result · 2018-10-15

Clinical Trial Update: Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) [Phase 3]

Phase 3 trial of avelumab in third-line gastric cancer has completed; results were posted in 2018.

CLINICAL_TRIALS withdrawal · 2018-07-13

Clinical Trial Update: A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach [Phase 2]

This Phase 2 trial evaluating perioperative mFOLFOX6 plus pembrolizumab for potentially resectable gastroesophageal junction and stomach ade…

CLINICAL_TRIALS trial_result · 2018-05-21

Clinical Trial Update: Siewert Type I-II: CT, PET-CT, EUS Sensitivity/Specificity for the Assessment of Lymph Node Metastases

Completed clinical trial comparing CT, PET-CT, and EUS for detecting lymph node metastases in Siewert Type I-II esophageal/gastroesophageal …

CLINICAL_TRIALS trial_result · 2018-05-02

Clinical Trial Update: A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer [Phase 3]

Phase 3 trial of ramucirumab with capecitabine and cisplatin in metastatic gastric/GEJ adenocarcinoma completed with results posted in 2018.

Top drugs studied for this disease